Compare Stocks: NERV, ZVRA, CRMD, and PHAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.85	$7.90	$6.13 ▼ $13.02	$611.83M	1.5	831,338 shs	606,605 shs
NERV Minerva Neurosciences	$3.40	$4.27	$2.06 ▼ $12.46	$162.34M	-0.08	163,051 shs	103,312 shs
PHAT Phathom Pharmaceuticals	$7.30	$9.09	$6.91 ▼ $18.31	$590.57M	0.51	1.23 million shs	1.44 million shs
ZVRA Zevra Therapeutics	$11.04	$11.48	$8.01 ▼ $15.03	$655.56M	0.95	858,989 shs	669,425 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	0.00%	+1.68%	-5.42%	+2.75%	-30.53%
NERV Minerva Neurosciences	0.00%	-7.10%	-29.75%	-37.38%	+60.38%
PHAT Phathom Pharmaceuticals	0.00%	-2.41%	-20.48%	-32.84%	-38.03%
ZVRA Zevra Therapeutics	0.00%	-4.91%	-4.50%	-21.20%	+13.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.85	$7.90	$6.13 ▼ $13.02	$611.83M	1.5	831,338 shs	606,605 shs
NERV Minerva Neurosciences	$3.40	$4.27	$2.06 ▼ $12.46	$162.34M	-0.08	163,051 shs	103,312 shs
PHAT Phathom Pharmaceuticals	$7.30	$9.09	$6.91 ▼ $18.31	$590.57M	0.51	1.23 million shs	1.44 million shs
ZVRA Zevra Therapeutics	$11.04	$11.48	$8.01 ▼ $15.03	$655.56M	0.95	858,989 shs	669,425 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	0.00%	+1.68%	-5.42%	+2.75%	-30.53%
NERV Minerva Neurosciences	0.00%	-7.10%	-29.75%	-37.38%	+60.38%
PHAT Phathom Pharmaceuticals	0.00%	-2.41%	-20.48%	-32.84%	-38.03%
ZVRA Zevra Therapeutics	0.00%	-4.91%	-4.50%	-21.20%	+13.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.78	Moderate Buy	$15.00	91.08% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	203.92% Upside
PHAT Phathom Pharmaceuticals	2.78	Moderate Buy	$21.25	191.10% Upside
ZVRA Zevra Therapeutics	2.90	Moderate Buy	$27.14	145.86% Upside

Current Analyst Ratings Breakdown

Latest NERV, ZVRA, CRMD, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CRMD CorMedix	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$15.00
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$10.00
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$10.00
8/20/2026	ZVRA Zevra Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
8/19/2026	ZVRA Zevra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$311.71M	1.96	$2.04 per share	3.84	$5.14 per share	1.53
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
PHAT Phathom Pharmaceuticals	$175.11M	3.37	N/A	N/A	($6.14) per share	-1.19
ZVRA Zevra Therapeutics	$106.47M	6.16	$0.95 per share	11.67	$2.75 per share	4.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	$163.05M	$2.14	3.67	56.07	1.45	40.49%	40.52%	20.61%	11/11/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	6.29	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)
ZVRA Zevra Therapeutics	$83.23M	$0.92	12.00	13.14	N/A	42.82%	54.54%	34.15%	11/4/2026 (Estimated)

Latest NERV, ZVRA, CRMD, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
8/5/2026	Q2 2026	ZVRA Zevra Therapeutics	$0.11	$0.25	+$0.14	$0.14	$33.88 million	$39.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	0.31	2.56	2.36
NERV Minerva Neurosciences	N/A	20.15	20.14
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87
ZVRA Zevra Therapeutics	N/A	5.17	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
NERV Minerva Neurosciences	34.56%
PHAT Phathom Pharmaceuticals	99.01%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.50%
NERV Minerva Neurosciences	1.70%
PHAT Phathom Pharmaceuticals	9.33%
ZVRA Zevra Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	191	77.94 million	75.22 million	Optionable
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable
PHAT Phathom Pharmaceuticals	371	80.90 million	73.35 million	Optionable
ZVRA Zevra Therapeutics	61	59.38 million	57.19 million	Optionable

NERV, ZVRA, CRMD, and PHAT Headlines

Recent News About These Companies

Stock Traders Buy Large Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

September 25 at 5:01 AM | americanbankingnews.com

Stock Traders Buy High Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

September 24, 2026 | marketbeat.com

Financial Contrast: Zevra Therapeutics (NASDAQ:ZVRA) and Daiichi Sankyo (OTCMKTS:DSNKY)

September 24, 2026 | americanbankingnews.com

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

September 13, 2026 | marketbeat.com

Bank of America Corp DE Decreases Stock Position in Zevra Therapeutics, Inc. $ZVRA

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $2.85 Million in Zevra Therapeutics, Inc. $ZVRA

September 7, 2026 | marketbeat.com

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium

August 25, 2026 | quiverquant.comQ

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026 | globenewswire.com

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

August 23, 2026 | theglobeandmail.com

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 13, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 11, 2026 | globenewswire.com

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

August 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 6, 2026 | prnewswire.com

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

August 6, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

August 5, 2026 | zacks.com

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

August 5, 2026 | quiverquant.comQ

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

August 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, ZVRA, CRMD, and PHAT Company Descriptions

CorMedix NASDAQ:CRMD

$7.85 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.82 -0.03 (-0.34%)

As of 09/25/2026 07:56 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Minerva Neurosciences NASDAQ:NERV

$3.40 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.40 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$7.30 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.30 +0.00 (+0.07%)

As of 09/25/2026 07:30 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Zevra Therapeutics NASDAQ:ZVRA

$11.04 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$11.27 +0.23 (+2.07%)

As of 09/25/2026 07:30 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, ZVRA, CRMD, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, ZVRA, CRMD, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, ZVRA, CRMD, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, ZVRA, CRMD, and PHAT Company Descriptions

CorMedix NASDAQ:CRMD

Minerva Neurosciences NASDAQ:NERV

Phathom Pharmaceuticals NASDAQ:PHAT

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, ZVRA, CRMD, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, ZVRA, CRMD, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, ZVRA, CRMD, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, ZVRA, CRMD, and PHAT Company Descriptions

CorMedix NASDAQ:CRMD

Minerva Neurosciences NASDAQ:NERV

Phathom Pharmaceuticals NASDAQ:PHAT

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools